Subscribe To

Price Alert Latest News Economic Calendar News

SRPT / Sarepta Therapeutics downgraded at Evercore ISI after FDA approval of gene therapy

Sarepta Therapeutics Inc. SRPT, -2.33%, which yesterday scored a win with U.S. Food and Drug Administration approval of the first gene therapy for children with Duchenne muscular dystrophy, was downgraded Friday by analysts who are skeptical that Sarepta can expand the treatment's narrow label. The treatment, Elevidys, was approved under the FDA's accelerated approval pathway, which gives patients access to promising new treatments while the company conducts trials to confirm the expected clinical benefit. Read More

Demo Live Account See Partner Details

Content Topics

Sarepta

Therapeutics

Downgraded

Evercore

After

Approval

Gene

Therapy

Stock

SRPT

Posted: Jun 23 2023, 08:21

Author Name: Market Watch

SRPT News

By Investors Business Daily
October 31, 2023

Sarepta Crashes 39% After Its Gene Therapy Flops Its Biggest-Ever Test

Sarepta Therapeutics' gene therapy, Elevidys, faces an uphill regulatory journey, analysts said Tuesday on mixed test results.

By Barrons
October 31, 2023

Sarepta Stock Sinks on Mixed Gene Therapy Results

In a gene therapy study for patients with Duchenne muscular dystrophy, the primary endpoint was not met.

By Investors Business Daily
October 30, 2023

Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene Therapy

Sarepta unveiled mixed results late Monday for a gene therapy that targets a muscle-wasting disease in boys. SRPT stock was halted.

By Reuters
October 30, 2023

Sarepta's gene therapy fails to meet primary goal in rare muscular dystrophy trial

Sarepta Therapeutics' gene therapy to treat Duchenne muscular dystrophy failed to reach statistical significance in a late-stage trial, the company re

By The Motley Fool
August 23, 2023

Is Sarepta Therapeutics Stock a Top Growth Vehicle?

Wall Street is expecting big things from the rare disease specialist Sarepta Therapeutics in 2023 and beyond. However, the company does face some impo

By Seeking Alpha
August 2, 2023

Sarepta Therapeutics, Inc. (SRPT) Q2 2023 Earnings Call Transcript

Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Francesca Nolan - IR Directo

By Zacks Investment Research
August 2, 2023

Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates

Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $1.89. This compares to

By Zacks Investment Research
July 25, 2023

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.